SS Innovations International (NASDAQ: SSII) has announced significant growth in the adoption of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026. This represents a 79% increase from 7,885 procedures at the end of 2025, underscoring the system's expanding role in global surgery. The installed base of SSi Mantra systems climbed to 238, up 42% from 168 at year-end, and now spans 12 countries following recent launches in Colombia and Sri Lanka. Approximately 1,500 physicians have been trained on the platform, further supporting its integration into clinical practice.
The implications of this growth are substantial. The rapid rise in procedure volume and installations indicates that SSi Mantra is gaining traction in both established and emerging markets, potentially challenging the dominance of larger robotic surgery players. The expansion into pediatric applications is particularly notable: a robotic kidney procedure was performed on a 45-day-old infant in India using 5-millimeter instruments, demonstrating the system's versatility and precision for delicate procedures. This could open new avenues for minimally invasive pediatric surgery, where smaller instruments are critical.
Additionally, the company reported 188 cumulative robotic telesurgeries as of August 31, including long-distance procedures connecting surgeons and patients across countries. This highlights the potential of SSi Mantra to enable remote surgery, which could improve access to specialized care in underserved regions. The continued development of telesurgery capabilities may also position SS Innovations as a leader in telemedicine-enabled surgical robotics.
Regulatory milestones are on the horizon. SS Innovations expects FDA review of its 510(k) submission for SSi Mantra by the end of Q1 2027 and believes EU CE marking could be obtained by the end of 2026. Achieving these certifications would be pivotal, allowing the company to enter the large U.S. and European markets. This could significantly accelerate revenue growth and further validate the technology's safety and efficacy. For investors, these regulatory catalysts represent key events that could drive the company's valuation.
The broader impact of SS Innovations' expansion extends to the competitive landscape of surgical robotics. With a growing installed base and procedure count, the company is demonstrating that its technology is not only viable but increasingly preferred in certain applications. This could pressure competitors to innovate and potentially lower costs, benefiting healthcare systems globally. Moreover, the focus on telesurgery and pediatric applications addresses unmet needs, potentially improving patient outcomes and expanding the total addressable market.
For those tracking the company's progress, the latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. The full release can be viewed on www.newmediawire.com, and additional details are available through SS Innovations International (NASDAQ: SSII).
As SS Innovations continues to expand its global footprint, the coming months will be critical. The anticipated regulatory decisions and ongoing adoption of SSi Mantra in new surgical specialties could solidify its position as a major player in the surgical robotics market. The company's ability to execute on these fronts will determine whether it can sustain its growth trajectory and deliver long-term value to stakeholders.
